Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

143
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
143

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

The impact of PSMA-PET/CT on clinical decision-making in primary staging of prostate cancer.

EJNMMI research·2026
Same author

Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.

NMR in biomedicine·2026
Same author

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

PloS one·2026
Same author

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

Prostate cancer and prostatic diseases·2026

Related Experiment Video

Updated: Sep 30, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

412

Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With

Aseem Anand1, Glenn Heller2, Joseph Fox3

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Translational Medicine, Division of Urological Cancers, Malmö, Lund University, Lund, Sweden.

Clinical Genitourinary Cancer
|March 13, 2022
PubMed
Summary
This summary is machine-generated.

An absolute increase of 0.6 in automated bone scan index (aBSI) best correlates with overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients. This finding may refine progression criteria for mCRPC bone disease.

Keywords:
Imaging biomarkersbone metastasesclinical trials endpoints

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Related Experiment Videos

Last Updated: Sep 30, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

412
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • Radiographic progression-free survival (rPFS) using Prostate Cancer Working Group (PCWG) criteria is a key endpoint in metastatic castration-resistant prostate cancer (mCRPC).
  • The automated bone scan index (aBSI) quantifies bone disease burden on scintigraphy.
  • The relationship between aBSI changes and overall survival (OS) needs further clarification.

Purpose of the Study:

  • To quantify tumor burden increase using aBSI that aligns with PCWG progression criteria.
  • To determine the specific aBSI increase threshold most strongly associated with OS in mCRPC patients.

Main Methods:

  • Retrospective analysis of mCRPC patients treated with androgen receptor axis-targeted drugs.
  • Assessment of aBSI increase from baseline to progression (defined by PCWG criteria).
  • Exploration of time-to-threshold for aBSI increase and its association with OS.

Main Results:

  • Of 169 mCRPC patients, 90 (53%) met PCWG bone progression criteria.
  • Median relative aBSI increase was 109% in patients with PCWG progression.
  • An absolute aBSI increase of 0.6 demonstrated the strongest association with OS.

Conclusions:

  • An absolute aBSI increase of ≥0.6 from the first follow-up scan is highly associated with OS in mCRPC.
  • PCWG criteria identified progression at a higher tumor burden than this optimal aBSI threshold.
  • aBSI can potentially refine PCWG criteria for mCRPC progression assessment without compromising OS association.